25T2-NBOMe
Pharmaceutical compound
From Wikipedia, the free encyclopedia
25T2-NBOMe, also known as N-(2-methoxybenzyl)-4-ethylthio-2,5-dimethoxyphenethylamine, is a serotonergic psychedelic of the 25-NB (NBOMe) family.[2][3][4][5][6][7] It is the NBOMe analogue of 2C-T-2.[2][3][4][5][6][7]
- None
| Clinical data | |
|---|---|
| Other names | 2C-T-2-NBOMe; NBOMe-2C-T-2; N-(2-Methoxybenzyl)-4-ethylthio-2,5-dimethoxyphenethylamine |
| Routes of administration | Sublingual[1] |
| Drug class | Serotonin 5-HT2 receptor agonist; Serotonergic psychedelic; Hallucinogen |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C20H27NO3S |
| Molar mass | 361.50 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Use and effects
25T2-NBOMe's reported active dose range in humans has been described as 100 to 1,000 μg, with a typical dose estimate of 500 μg.[1] The route is sublingual administration.[1]
Interactions
Pharmacology
Pharmacodynamics
| Target | Affinity (Ki, nM) |
|---|---|
| 5-HT1A | 2,200 |
| 5-HT1B | ND |
| 5-HT1D | ND |
| 5-HT1E | ND |
| 5-HT1F | ND |
| 5-HT2A | 0.56–0.6 (Ki) 4.37–100 (EC50) 38–81% (Emax) |
| 5-HT2B | 0.85 (Ki) 40 (EC50) 31% (Emax) |
| 5-HT2C | 6.5 (Ki) 12.0 (EC50) 103% (Emax) |
| 5-HT3 | ND |
| 5-HT4 | ND |
| 5-HT5A | ND |
| 5-HT6 | 84.9 |
| 5-HT7 | ND |
| α1A | 550 |
| α1B, α1D | ND |
| α2A | 450 |
| α2B, α2C | ND |
| β1–β3 | ND |
| D1 | 7,700 |
| D2 | 1,600 |
| D3 | 3,000 |
| D4, D5 | ND |
| H1 | 490 |
| H2–H4 | ND |
| M1–M5 | ND |
| I1 | ND |
| σ1, σ2 | ND |
| ORs | ND |
| TAAR1 | 4,200 (Ki) (mouse) 350 (Ki) (rat) 2,900 (EC50) (mouse) 930 (EC50) (rat) >10,000 (EC50) (human) 30% (Emax) (mouse) 24% (Emax) (rat) |
| SERT | 5,000 (Ki) 20,000 (IC50) ND (EC50) |
| NET | 5,900 (Ki) 25,000 (IC50) ND (EC50) |
| DAT | 8,600 (Ki) 67,000 (IC50) ND (EC50) |
| Notes: The smaller the value, the more avidly the drug binds to the site. All proteins are human unless otherwise specified. Refs: [8][9][10][11][12] | |
25T2-NBOMe acts as a highly potent and selective agonist of the serotonin 5-HT2 receptors.[11] Its affinities and activities at a variety of other receptors and transporters have also been described.[11]
History
25T2-NBOMe was first described in the scientific literature by at least 2012.[13]
Society and culture
Legal status
Canada
25T2-NBOMe is a controlled substance in Canada under phenethylamine blanket-ban language.[14]